.png)
Share
Anne E. Borgman
Circle Pharma, Inc., a clinical-stage biopharmaceutical company developing next-generation targeted macrocycle therapeutics for cancer, has appointed Anne E. Borgman, M.D., as Chief Medical Officer.
Dr. Borgman brings more than 20 years of experience in oncology drug development, with a strong track record of designing and executing clinical strategies that have led to multiple regulatory approvals.
Before joining Circle Pharma, Dr. Borgman served as Chief Medical Officer at Sutro Biopharma, where she advanced the company’s lead program into pivotal clinical trials in ovarian cancer and infant leukemia. Earlier, she was Vice President and Therapeutic Area Lead for Oncology, Hematology, and Transplant at Jazz Pharmaceuticals. In this role, she led global drug development for four marketed products - Defitelio®, VYXEOS®, ZEPZELCA®, and RYLAZE® - sand oversaw development strategies for several emerging oncology targets.
Dr. Borgman previously held the position of Vice President, Clinical Research and Development, at Exelixis, where she played a key role in the global development of cabozantinib and led the execution of multiple Phase 3 clinical trials. Her earlier career includes senior leadership roles at KaloBios Pharmaceuticals, Talon Therapeutics (formerly Hana Biosciences), and Abbott Laboratories. At Abbott, she served as global project head and helped shape early development strategies for venetoclax and veliparib.
In addition to her executive roles, Dr. Borgman currently serves on the boards of directors of clinical-stage oncology companies NextCure, Curis, and NiKang. She earned her M.D. from Loyola University Chicago Stritch School of Medicine, completed pediatric residency training at Baylor College of Medicine, and pursued fellowship training in pediatric hematology-oncology and bone marrow transplantation at UCLA. She holds a B.S. in biochemistry from the University of Illinois.
